Results 61 to 70 of about 4,367 (184)

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

, 2023
225231OBJECTIVE: To evaluate risankizumab, a biological therapy that inhibits interleukin 23, in patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to ≥1 conventional synthetic disease-modifying antirheumatic
Papp, K., Eldred, A., Lu, W., Kristensen, L.E., Soliman, A.M., Behrens, Frank, Keiserman, M., White, D., Wang, Z., McCasland, L., Barcomb, L.   +10 more
core   +1 more source

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

Dermatology and Therapy
Introduction Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of ...
Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi   +14 more
doaj   +1 more source

Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison [PDF]

Anais Brasileiros de Dermatologia
Background: Psoriasis is a chronic inflammatory skin disease with a genetic predisposition and autoimmune component, often treated with immunomodulators such as biologic therapies.
Leyla Baykal Selçuk, Hande Ermiş Akkuş, Burak Akşan, Deniz Aksu Arıca   +3 more
doaj   +1 more source

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

International Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab

Pediatric Dermatology, EarlyView.
ABSTRACT Bowel‐associated dermatosis‐arthritis syndrome (BADAS) is a rare neutrophilic dermatosis characterized by recurrent fever, arthralgias, and skin eruptions, most commonly occurring in patients with inflammatory bowel disease. We report the case of a 17‐year‐old female with Crohn's disease who developed BADAS and achieved complete and durable ...
Kylie E. Peake, Harman Toor, Marie‐Christine Jean, Collin C. Barker, Joseph M. Lam   +4 more
wiley   +1 more source

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis

, 2020
Objective: Risankizumab (Skyrizi), an interleukin-23 (IL-23) antagonist, was approved by the Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in April 2019.
Haidari, Wasim, Feldman, Steven R., Ghamrawi, Rima, Li, Wendy   +3 more
core   +1 more source

Selective IL‐23 Inhibition in Conventional Treatment‐Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study

International Journal of Dermatology, Volume 65, Issue 10, Page 2055-2065, October 2026.
The clinical effects of selective IL‐23 inhibition in refractory pyoderma gangrenosum, highlighting progressive ulcer healing, reduction in inflammation and pain, and steroid‐sparing effect, supporting the role of the IL‐23/Th17 axis as a therapeutic target.
Luca Bettolini, Carlo Alberto Maronese, Federica Derlino, Giovanni Genovese, Chiara Moltrasio, Luisa Sarno, Stefano Buffon, Bianca Cei, Giammarco Granieri, Valentina Dini, Marco Romanelli, Vincenzo Maione, Stefano Bighetti, Marina Venturini, Edoardo Cammarata, Paola Savoia, Antonio Di Guardo, Luigi Gargiulo, Ruggero Cascio Ingurgio, Antonio Costanzo, Lorenza Burzi, Claudia Leporati, Nunzia Di Cristo, Nicola Zerbinati, Alex G. Ortega‐Loayza, Angelo Valerio Marzano   +25 more
wiley   +1 more source

Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review

Immunity, Inflammation and Disease, Volume 14, Issue 9, September 2026.
ABSTRACT Background Psoriatic arthritis (PsA) is a chronic inflammatory disease with complex pathophysiology. Despite advancements in biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs), treatment responses remain suboptimal for many patients.
Mengduan Pang, Ling Li, Qi Zhang, Min Zhao   +3 more
wiley   +1 more source